Mechanism of Action

GLP-3R is a first-in-class triple-agonist peptide that simultaneously activates GIP, GLP-1, and glucagon receptors. This triple mechanism provides synergistic metabolic signaling: GIP and GLP-1 modulate insulin secretion, while glucagon receptor activation modulates hepatic fat oxidation pathways. In a comparative research context, GLP-3R is referenced as a structural analog of retatrutide — the triple-agonist compound described in the published peer-reviewed literature (Jastreboff et al., 2023) — and is supplied solely as a reference research compound for in-vitro laboratory study. It is not retatrutide, not an approved drug, and not a substitute for any approved medication. For research purposes only.

Research Observations

• Triple receptor activation for comprehensive metabolic pathway modulation
• GIP, GLP-1, and glucagon receptor signaling studied simultaneously
• Hepatic steatosis and liver pathway observations in preclinical models
• Glycemic modulation with HbA1c pathway observations in clinical studies
• Novel triple-agonist mechanism studied as a new class of compound